Biotech | August 18, 2021
ANG Lifesciences acquires Ind-Swift formulation facilities for Rs 60 cr
The company expects a potential sales turnover of Rs.350-500 crores at 100 % capacity utilization
The company expects a potential sales turnover of Rs.350-500 crores at 100 % capacity utilization
Cosentyx is a proven treatment, supported by long-term five-year sustained efficacy and safety data across several inflammatory conditions and with more than 500,000 patients treated worldwide since launch
Results from year two of the pivotal Phase 3 KITE clinical trial reaffirmed visual acuity gains and fluid reduction findings as well as safety profile from year one
Seen in 1 in 3 million births, the malformation was detected at the antenatal stage during the mother's pregnancy
India’s dependency on China for pharma intermediates can change if there is a proper coordination between educational institutes, research institutes and pharma manufacturers
This multi-centre study (sites in the US and Europe) comprising about 387 patients is likely to be completed in about 36 months and the topline result is expected by the end of 2024
_256_384.jpg)
The focus of this year’s challenge is to find solutions within Covid management and treatment of cardiovascular, renal, neuro, cancer and lung diseases
_256_384.png)
MTL, with over 40 years of experience in packaging, caters to the requirements of the FMCG, F&B, homecare, personal care, agrochemicals, pharmaceutical, and liquor industries
The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.
Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older
Subscribe To Our Newsletter & Stay Updated
